Abstract
In this issue of Blood, Albertsson-Lindblad et al report on the efficacy of a bendamustine (B)/lenalidomide (LEN)/rituximab (R) combination in first-line therapy of mantle cell lymphoma (MCL). Essentially, this combination achieved high response rates (complete response, 64%;molecular remission, 36%) and a prolonged median progression-free survival (PFS) of 42 months, but rate of infections (42%) and secondary malignancies (16%) were significant. 1 So how should we evaluate these results in light of other trials?
Dokumententyp: | Zeitschriftenartikel |
---|---|
Fakultät: | Medizin |
Themengebiete: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit |
ISSN: | 0006-4971 |
Sprache: | Englisch |
Dokumenten ID: | 43769 |
Datum der Veröffentlichung auf Open Access LMU: | 27. Apr. 2018, 08:04 |
Letzte Änderungen: | 04. Nov. 2020, 13:19 |